Intercure Ltd. INCR
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Intercure Ltd. (INCR) is a healthcare company listed in the US with a market value of about $57M. In fiscal year 2024 it had revenue of $65M and net income of -$19M, a net margin of -28.4%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 91% a year, a 5-year average ROIC of -3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 41% below the current price.
About Intercure
Intercure is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $3M in 2019 to $65M in 2024, growth of about 90.9% a year. It was profitable in 2 of the last 6 years in our data.
Score: 0.8 / 5
Checks passed
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | $65M | $98M | $110M | $71M | $20M | $3M |
| Net income | -$19M | -$17M | $13M | $2M | -$12M | -$2M |
| Free cash flow | -$20M | -$16M | $9M | $5M | -$4M | -$11M |
| EPS (diluted) | $-1.24 | $-1.14 | $0.85 | $0.10 | $-0.77 | $-0.11 |
| Net margin | -28.4% | -17.4% | 11.5% | 2.1% | -57.2% | -66.0% |
| ROIC | -9.7% | -5.2% | 6.9% | 4.2% | -13.1% | -1.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Intercure stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 41% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Intercure pay a dividend?
Not currently.
Is Intercure a good stock to buy?
We do not give buy or sell advice. Intercure scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.